Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11215361 | 0.98 | KDM4E (0.40) | MAPK1KDM4EHSD17B10MCL1SMN1; SMN2 | |
| SCHEMBL15475264 | 0.94 | THRB (0.38) | MAPK1KDM4EHSD17B10TSHRCYP1A2 | |
| SCHEMBL15415222 | 0.81 | KDM4E (0.40) | MAPK1KDM4EHSD17B10MCL1SMN1; SMN2 | |
| SCHEMBL3171 | 0.81 | MAPK1 (0.54) | MAPK1KDM4EHSD17B10MCL1SMN1; SMN2 | |
| SCHEMBL7305358 | 0.81 | MAPK1 (0.54) | MAPK1KDM4EHSD17B10MCL1SMN1; SMN2 | |
| SCHEMBL20303983 | 0.81 | MAPK1 (0.54) | MAPK1KDM4EHSD17B10MCL1SMN1; SMN2 | |
| SCHEMBL1615850 | 0.79 | MAPK1 (0.53) | MAPK1KDM4EHSD17B10MCL1SMN1; SMN2 | |
| SCHEMBL7199566 | 0.79 | MAPK1 (0.53) | MAPK1KDM4EHSD17B10MCL1SMN1; SMN2 | |
| SCHEMBL3767660 | 0.79 | MAPK1 (0.53) | MAPK1KDM4EHSD17B10MCL1SMN1; SMN2 | |
| SCHEMBL6248372 | 0.79 | MAPK1 (0.53) | MAPK1KDM4EHSD17B10MCL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109231-B2 | Cyclohept[b]indole derivatives | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1438290-B1 | CYCLOHEPT B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040198801-A1 | Cyclohept'b!indole derivatives as spla2 inhibitors | KINNICK MICHAEL DEAN (US) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198801-A1 | Cyclohept'b!indole derivatives as spla2 inhibitors | SPTSSB, CPT1A, TPH2 | MAPK1 4341/4885KDM4E 3426/4885HSD17B10 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.